Chronic liver disease is universal in children with biliary atresia living with native liver

Way Seah Lee1, Sik Yong Ong1, Hee Wei Foo1

  • 1Department of Paediatrics, University Malaya Medical Centre, Kuala Lumpur 59100, Malaysia.

Insights

Most children with biliary atresia (BA) surviving with native livers show signs of chronic liver disease (CLD). Early medical surveillance is crucial for detecting complications like portal hypertension and variceal bleeding in young children with BA.

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Surgical Outcomes

Background:

  • Biliary atresia (BA) is a severe neonatal liver disease.
  • Native liver survival after hepatoportoenterostomy is a critical outcome.
  • Long-term medical status of these children requires thorough investigation.

Purpose of the Study:

  • To assess the medical status of children with BA who survive with their native livers.
  • To identify the prevalence of chronic liver disease (CLD) complications in this cohort.
  • To define an ideal medical outcome and evaluate its occurrence.

Main Methods:

  • Cross-sectional review of medical data from 52 children with BA surviving with native livers.
  • Collected data included complications of CLD (cholangitis, portal hypertension, variceal bleeding, etc.) and laboratory indices.
  • Ideal medical outcome defined as absence of clinical CLD evidence and normal laboratory indices.

Main Results:

  • 98% of children exhibited clinical or laboratory evidence of CLD.
  • Common complications included portal hypertension (40%), cholangitis (36%), and variceal bleeding (25%).
  • An ideal medical outcome was observed in only 2% of patients.

Conclusions:

  • Children with BA surviving with native livers frequently have evidence of CLD.
  • Portal hypertension and variceal bleeding can occur even in children under 5 years old.
  • Emphasizes the need for early and continuous medical surveillance for BA complications.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
820
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
258